Genentech neoantigen deal gives Vaccibody runway to speed up infectious disease pipeline  

Having licensed its neoantigen cancer vaccine to Genentech for $200 million in upfront and near-term payments, Norwegian biotech Vaccibody will use the proceeds to advance the infectious disease research it kicked off in April.

Thursday’s deal gives the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) exclusive, global rights to VB10.NEO, a personalized DNA-based neoantigen vaccine. Vaccibody is further eligible for $515 million in milestones plus tiered, low double-digit royalties...